Tune Therapeutics Moves into Clinical Spotlight with TUNE-401: A First-in-Class Epigenetic Silencer for Hepatitis B
11/14/2024
Portfolio News
New
TUNE-401 will be the first epigenetic therapy to enter clinical trials for an infectious disease
United Immunity enters into a Research Collaboration Agreement with AstraZeneca
07/26/2024
Portfolio News
United Immunity develops its proprietary active targeting pullulan lipid nanoparticle (LNP) selective to myeloid cells as its Myeloid Targeting Platform.
Kenai Therapeutics Announces $82 Million Series A Financing to Advance Next Generation Allogeneic Cell Therapies for Neurological Diseases
02/29/2024
Portfolio News
Proceeds to be used to complete clinical proof-of-concept trial for lead candidate, RNDP-001, for the treatment of Parkinson’s disease.